Announcements Trials
Browse Landscape

Phase

Phase NA 3Phase 3 2Phase EARLY_PHASE1 1Phase 2 1Phase 1 1

Status

Unknown 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 4Plasma cell 2Other hematologic neoplasm 2Gastrointestinal 2Thoracic 1Myeloid 1Gynecologic 1

Conditions

Vomiting 2Neoplasms, Plasma Cell 1Nausea 1Multiple Myeloma 1

Interventions

Dexamethasone 178Bortezomib 100Lenalidomide 90daratumumab 47Melphalan 46Thalidomide 44pomalidomide 43Cyclophosphamide 38Calcium Dobesilate 30carfilzomib 29Prednisone 19Doxorubicin 16elotuzumab 14Filgrastim 14isatuximab 12ixazomib 11Granulocyte Colony-Stimulating Factor 11Vincristine 10Peripheral Blood Stem Cell Transplantation 10dexamethasone acetate 9belantamab mafodotin 9Zoledronic Acid 8selinexor 7Epoetin Alfa 7fludarabine 6Etoposide 6dexamethasone 21-phosphate 5auricularum 5Mycophenolic Acid 5Cisplatin 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Aprepitant × Plasma cell × Clear all
NCT02939287 2024-10-22

Aprepitant- and Olanzapine- Containing Anti-emetic Regimens With High Dose Melphalan

Rush University Medical Center

Phase 3 Completed
52 enrolled 11 charts
Plasma cell

Nausea, Vomiting, Neoplasms, Plasma Cell

NCT00571168 2010-01-12

EmNa

Heidelberg University

Phase 3 Unknown
362 enrolled
Plasma cell

Multiple Myeloma, Vomiting

Data powered by HemOnc (CC BY 4.0) Colophon âš¡